Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „BCRP“
Suchtreffer
Begriffe & Kennungen
Adempas · 4.5 · 8 Concomitant use with strong multi pathway CYP and P-gp/BCRP inhibitors The concomitant use of riociguat with
Eintrag öffnenAdempas · 4.5 · Concomitant use with other CYP and P-gp/BCRP inhibitors Medicinal products strongly inhibiting P-gp/BCRP such
Eintrag öffnenAdempas · 4.5 · Concomitant use with other CYP and P-gp/BCRP inhibitors Medicinal products strongly inhibiting P-gp/BCRP such
Eintrag öffnenAdempas · 4.5 · Concomitant use with strong multi pathway CYP and P-gp/BCRP inhibitors The concomitant use of riociguat with s
Eintrag öffnenAkynzeo · 4.5 · In vitro data suggests that netupitant inhibits the efflux of transporter BCRP. The clinical relevance of this
Eintrag öffnenAkynzeo · 4.5 · Inhibition of the efflux transported BCRP and glucuronidation isozyme UGT2B7 by netupitant and its metabolites
Eintrag öffnenAlecensa · 4.5 · Breast cancer resistance protein (BCRP) substrates In vitro, alectinib and M4 are inhibitors of the efflux tra
Eintrag öffnenArava · 4.5 · Effect on BCRP (Breast Cancer Resistance Protein) and /or organic anion transporting polypeptide B1 and B3 (OA
Eintrag öffnenArava · 4.5 · Effect on BCRP (Breast Cancer Resistance Protein) and /or organic anion transporting polypeptide B1 and B3 (OA
Eintrag öffnenArava · 4.5 · Effect on BCRP (Breast Cancer Resistance Protein) and /or organic anion transporting polypeptide B1 and B3 (OA
Eintrag öffnenAubagio · 4.5 · Effect of teriflunomide on BCRP and /or organic anion transporting polypeptide B1 and B3 (OATP1B1/B3) substrat
Eintrag öffnenBeyonttra · 4.5 · Acoramidis is a substrate for BCRP. Based on an in vitro study, a clinically relevant interaction with BCRP in
Eintrag öffnenBiktarvy · 4.5 · (Inhibition of CYP3A, UGT1A1, and P-gp/BCRP) Atazanavir (400 mg once daily), Bictegravir: Bictegravir1 AUC: ↑
Eintrag öffnenBiktarvy · 4.5 · Bictegravir is both a P-gp and a BCRP substrate. The clinical relevance of this feature is not established. Th
Eintrag öffnenBiktarvy · 4.5 · Tenofovir alafenamide is transported by P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). Co-
Eintrag öffnenBosulif · 4.5 · In vitro studies indicate that bosutinib has a low potential to inhibit breast cancer resistance protein (BCRP
Eintrag öffnenBraftovi · 4.5 · Transporter substrates In vivo, encorafenib is an inhibitor of OATP1B1, OATP1B3 and/or BCRP. Coadministration
Eintrag öffnenBrilique · 4.5 · Rosuvastatin (BCRP substrate) Ticagrelor has been shown to increase rosuvastatin Cmax by approximately 2.5-fol
Eintrag öffnenBrilique · 4.5 · Rosuvastatin (BCRP substrate) Ticagrelor has been shown to increase rosuvastatin Cmax by approximately 2.5-fol
Eintrag öffnenBrilique · 4.5 · Rosuvastatin (BCRP substrate) Ticagrelor has been shown to increase rosuvastatin Cmax by approximately 2.5-fol
Eintrag öffnen